Literature DB >> 7951641

Violence toward women and illicit androgenic-anabolic steroid use.

P Y Choi1, H G Pope.   

Abstract

Substantial evidence now suggests that increased aggression is associated with illicit use of anabolic-androgenic steroids (AAS) by athletes. Anecdotal reports claim that wives and girlfriends of the athlete sometimes become victims of physical abuse when their significant other is using these drugs. We sought to investigate these claims empirically. Twenty-three AAS user strength athletes and 14 nonuser athletes, recruited in the course of a larger study, were interviewed using the Dyadic Adjustment Scale and the Conflict Tactics Scales to assess their relationships with their significant other. AAS users were asked about their relationship during their most recent "cycle" of AAS use and their most recent AAS-free period. Nonusers were asked about their relationship in the last 3 months. AAS users reported significantly more fights, verbal aggression, and violence toward their significant others when using AAS than when not using AAS. The AAS users on-drug differed significantly from nonusers on two of these indices, but AAS users off-drug did not significantly differ from nonusers. These findings support the anecdotal evidence that wives and girlfriends of AAS users may be at risk of serious injury from users while they are on-drug. Thus, AAS use may impose risks not only to the user, but also to the women close to them.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7951641     DOI: 10.3109/10401239409148835

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  22 in total

Review 1.  Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern?

Authors:  Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Drug Alcohol Depend       Date:  2008-07-02       Impact factor: 4.492

2.  National Athletic Trainers' Association position statement: anabolic-androgenic steroids.

Authors:  Robert D Kersey; Diane L Elliot; Linn Goldberg; Gen Kanayama; James E Leone; Mike Pavlovich; Harrison G Pope
Journal:  J Athl Train       Date:  2012 Sep-Oct       Impact factor: 2.860

Review 3.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

4.  Increased dopaminergic and 5-hydroxytryptaminergic activities in male rat brain following long-term treatment with anabolic androgenic steroids.

Authors:  I Thiblin; A Finn; S B Ross; C Stenfors
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

Review 5.  The use of anabolic androgenic steroids and polypharmacy: a review of the literature.

Authors:  Tonya Dodge; Margaux F Hoagland
Journal:  Drug Alcohol Depend       Date:  2011-01-12       Impact factor: 4.492

6.  Mood Symptoms in Steroid Users: The Unexamined Role of Concurrent Stimulant Use.

Authors:  Pilar M Sanjuan; James L Langenbucher; Tom Hildebrandt
Journal:  J Subst Use       Date:  2015-09-18

Review 7.  Effects of androgenic-anabolic steroids in athletes.

Authors:  Fred Hartgens; Harm Kuipers
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

Review 8.  Illicit anabolic-androgenic steroid use.

Authors:  Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Horm Behav       Date:  2009-09-18       Impact factor: 3.587

Review 9.  Anabolic-androgenic steroid dependence? Insights from animals and humans.

Authors:  Ruth I Wood
Journal:  Front Neuroendocrinol       Date:  2008-01-03       Impact factor: 8.606

Review 10.  The effect of increased serotonergic neurotransmission on aggression: a critical meta-analytical review of preclinical studies.

Authors:  Maria Carrillo; Lesley A Ricci; Glen A Coppersmith; Richard H Melloni
Journal:  Psychopharmacology (Berl)       Date:  2009-04-30       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.